Austin Kirschner
Last active: 4/2/2019

Profile

My central theme of research is cancer biology with focus on developing new cancer treatments, especially for locally advanced and metastatic cancers that have limited treatments. I believe new cancer therapies should be targeted to specific cancer pathways to limit their toxicity and side effects, while providing effective treatment. I am a physician-scientist treating cancer patients in a department of radiation oncology and perform basic science and translational research investigating new cancer therapies and mechanisms. Ultimately, my goal is to directly translate my research findings into clinical trials with patients. My current research focuses on prostate cancer, since there is a significant clinical deficit: nearly 30,000 men die from prostate cancer each year in the USA, making it the #2 cause of cancer death in men (world-wide: 1.1 million diagnosed and 307,000 deaths). One research project studies a core mechanism in prostate cancer involving the oncogene PIM1 kinase, which has been implicated in numerous human malignancies, making it an important drug target for directed cancer therapy. I pursue research work that reveals PIM1-related mechanistic details in prostate cancer and demonstrates the efficacy of PIM1-directed inhibition for the treatment of prostate cancer. Another research project focuses on resistance to current cancer-directed therapies. Drugs that improve the effectiveness hormone therapy (androgen deprivation therapy), radiation therapy, and chemotherapy are needed to treat localized high-risk and metastatic disease. I study detailed mechanisms of the androgen receptor pathway, the DNA-damage repair pathway, and other pathways toward developing new therapeutic agents.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway. Sekhar KR, Wang J, Freeman ML, Kirschner AN (2019) PLoS One 14(4): e0214670
    › Primary publication · 30933998 (PubMed) · PMC6443157 (PubMed Central)
  2. Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literature. Khattab MH, Sherry AD, Ahlers CG, Kirschner AN (2018) World J Clin Oncol 9(8): 200-207
    › Primary publication · 30622928 (PubMed) · PMC6314863 (PubMed Central)
  3. Linear Accelerator-Based Stereotactic Radiosurgery for Cranial Intraparenchymal Metastasis of a Malignant Peripheral Nerve Sheath Tumor: Case Report and Review of the Literature. Fenlon JB, Khattab MH, Ferguson DC, Luo G, Keedy VL, Chambless LB, Kirschner AN (2019) World Neurosurg : 123-127
    › Primary publication · 30529515 (PubMed) · PMC6401255 (PubMed Central)
  4. Scalp-sparing total skin electron therapy in mycosis fungoides: Case report featuring a technique without lead. Patel CG, Ding G, Kirschner A (2017) Pract Radiat Oncol 7(6): 400-402
    › Primary publication · 28438420 (PubMed)
  5. Current Management of Refractory Germ Cell Tumors and Future Directions. Allen JC, Kirschner A, Scarpato KR, Morgans AK (2017) Curr Oncol Rep 19(2): 8
    › Primary publication · 28220447 (PubMed)
  6. Margin of error for a frameless image guided radiosurgery system: Direct confirmation based on posttreatment MRI scans. Luo G, Neimat JS, Cmelak A, Kirschner AN, Attia A, Morales-Paliza M, Ding GX (2017) Pract Radiat Oncol 7(3): e223-e231
    › Primary publication · 27720703 (PubMed)
  7. Radiotherapy-induced hemichorea. Isaacs D, Cmelak A, Kirschner AN, Phibbs F (2016) Neurology 86(14): 1355-1357
    › Primary publication · 26944270 (PubMed)
  8. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D, Abdulkadir SA (2015) J Natl Cancer Inst 107(2)
    › Primary publication · 25505253 (PubMed) · PMC4326311 (PubMed Central)
  9. Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate base. Kirschner AN, Sathiaseelan V, Zhang Y, David J, Kalapurakal JA (2014) J Contemp Brachytherapy 6(1): 33-9
    › Primary publication · 24790620 (PubMed) · PMC4003430 (PubMed Central)
  10. Treatment approach and outcomes of vaginal melanoma. Kirschner AN, Kidd EA, Dewees T, Perkins SM (2013) Int J Gynecol Cancer 23(8): 1484-9
    › Primary publication · 23945202 (PubMed)
  11. Trends in the use of postoperative radiation therapy in patients with localized resectable pancreatic cancer. Shinohara ET, Mitra N, Fei W, Kirschner AN, Metz JM (2012) Am J Clin Oncol 35(6): 543-8
    › Primary publication · 21926898 (PubMed)
  12. Eosinophilic pleural effusion complicating allergic bronchopulmonary aspergillosis. Kirschner AN, Kuhlmann E, Kuzniar TJ (2011) Respiration 82(5): 478-81
    › Primary publication · 21311176 (PubMed)
  13. Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex. Matsuura H, Kirschner AN, Longnecker R, Jardetzky TS (2010) Proc Natl Acad Sci U S A 107(52): 22641-6
    › Primary publication · 21149717 (PubMed) · PMC3012493 (PubMed Central)
  14. Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assays. Liu F, Marquardt G, Kirschner AN, Longnecker R, Jardetzky TS (2010) J Virol 84(19): 10375-85
    › Primary publication · 20668073 (PubMed) · PMC2937788 (PubMed Central)
  15. Characteristics of Epstein-Barr virus envelope protein gp42. Shaw PL, Kirschner AN, Jardetzky TS, Longnecker R (2010) Virus Genes 40(3): 307-19
    › Primary publication · 20162447 (PubMed) · PMC2854865 (PubMed Central)
  16. Structure of Epstein-Barr virus glycoprotein 42 suggests a mechanism for triggering receptor-activated virus entry. Kirschner AN, Sorem J, Longnecker R, Jardetzky TS (2009) Structure 17(2): 223-33
    › Primary publication · 19217393 (PubMed) · PMC3085316 (PubMed Central)
  17. Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion. Kirschner AN, Lowrey AS, Longnecker R, Jardetzky TS (2007) J Virol 81(17): 9216-29
    › Primary publication · 17581996 (PubMed) · PMC1951443 (PubMed Central)
  18. Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion. Kirschner AN, Omerovic J, Popov B, Longnecker R, Jardetzky TS (2006) J Virol 80(19): 9444-54
    › Primary publication · 16973550 (PubMed) · PMC1617263 (PubMed Central)
  19. X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60). Braden BC, Goldbaum FA, Chen BX, Kirschner AN, Wilson SR, Erlanger BF (2000) Proc Natl Acad Sci U S A 97(22): 12193-7
    › Primary publication · 11035793 (PubMed) · PMC17317 (PubMed Central)